A new sensitive chromogenic substrate assay of tissue factor pathway inhibitor type 1.
The present assay is a modification of our previously published two-stage chromogenic substrate assay of tissue factor pathway inhibitor type-1 (TFPI) activity [1]. In the first stage, the reaction mixture was made with factor VIIa (FVIIa) molecules in excess of tissue factor (TF) binding sites and contained diluted plasma, recombinant FVIIa (10 nM), recombinant TF (1/400 vol/vol), bovine factor Xa (1,1 nM), I-2882(R) (100 microg/ml), and CaCl(2) (10 mM). The fibrin polymerisation inhibitor I-2882(R) was added to the reaction mixture to prevent formation of cross-linked fibrin. In the second stage, residual TF/FVIIa catalytic activity was measured by the addition of a substrate mixture that contained bovine factor X and a chromogenic substrate (S-2222(R)). Standard curves were constructed using serial dilutions (0-1%) of pooled normal plasma. The dose-response relationship for serial dilutions of plasma was linear. The intra-assay coefficient of variations (CVs) for pre- and postheparin plasma samples (i.e., normal and high TFPI levels) were 1.7% and 9.9%, respectively; the inter-assay CVs were 10.0% and 19. 7%, respectively. The effect of variation in antithrombin activity on the assay was approximately 5%. The present assay correlated fairly well with our previously published assay (r=0.82, n=100) and with a commercial TFPI activity assay (Actichrome(R) TFPI Activity Assay, American Diagnostica, Greenwich, CT, USA; r=0.90, n=100), as well as with an antigen assay for TFPI total antigen (Imubind(R), American Diagnostica; r=0,96, n=100). Altman and Bland plots revealed that our previous assay underestimated TFPI activity at high TFPI levels (i.e., postheparin TFPI samples) compared with the other methods.
Bendz
B
B
Haematological Research Laboratory, Ullevâl University Hospital, N-0407, Oslo, Norway. bjorn.bendz@ioks.uio.no
Andersen
T O
TO
Sandset
P M
PM
D000577:Amides / Q000378:metabolism; D000818:Animals; D000991:Antithrombins / Q000494:pharmacology; D002417:Cattle; D002863:Chromogenic Compounds / Q000378:metabolism*; D015942:Factor VIIa / Q000378:metabolism; D015951:Factor Xa / Q000378:metabolism; D065427:Factor Xa Inhibitors; D005337:Fibrin / Q000037:antagonists & inhibitors / Q000378:metabolism; D006801:Humans; D008074:Lipoproteins / Q000097:blood*; D009842:Oligopeptides / Q000187:drug effects / Q000378:metabolism; D011517:Prothrombin Time; D011994:Recombinant Proteins / Q000378:metabolism; D015203:Reproducibility of Results; D013925:Thromboplastin / Q000378:metabolism; D013997:Time Factors
D000577:Amides; D000991:Antithrombins; D002863:Chromogenic Compounds; D065427:Factor Xa Inhibitors; D008074:Lipoproteins; D009842:Oligopeptides; D011994:Recombinant Proteins; C051928:lipoprotein-associated coagulation inhibitor; C015608:benzoyl-Ile-Glu-Gly-Arg-p-nitroanilide; D005337:Fibrin; D013925:Thromboplastin; D015942:Factor VIIa; D015951:Factor Xa